Key result
DAPT in ACS is linked to ~70% lower risk of insufficient antiplatelet effect versus aspirin alone.
Why the study?
Resistance to antiplatelet agents occurs in some patients, potentially increasing the risk of adverse cardiovascular events and atherothrombosis.
Does dual antiplatelet therapy or different doses of acetylsalicylic acid affect the suppression of platelet aggregation in hospitalized patients with cardiovascular or cerebrovascular diseases?
Observational
Does dual antiplatelet therapy or different doses of acetylsalicylic acid affect the suppression of platelet aggregation in hospitalized patients with cardiovascular or cerebrovascular diseases?
Absolute Event Rate: 8.2% vs 27.2%
p-value: p=0.0034
Dual antiplatelet therapy provides more pronounced suppression of platelet aggregation than acetylsalicylic acid alone, though resistance remains a clinical issue that may warrant aggregatometry testing.
No takes yet. Share an insight, caveat, or question.
DAPT was associated with fewer insufficient effects than aspirin alone in ACS; leaves open whether aggregometry should guide therapy.
Baturin et al. (2021) conducted an observational in Coronary heart disease, acute coronary syndrome, acute disorders of cerebral circulation. Acetylsalicylic acid in combination with clopidogrel vs. Acetylsalicylic acid alone was evaluated on Insufficient antiplatelet effect (p=0.0034). Dual antiplatelet therapy in acute coronary syndrome patients showed insufficient antiplatelet effect in 8.2% of cases compared to 27.2% in coronary heart disease patients on aspirin alone (p=0.0034).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: